Maxime Ranger
Directeur Général chez Giiant Pharma, Inc.
Profil
Maxime Ranger was the founder of gIcare Pharma, Inc. (founded in 2011) where he held the title of Chief Executive Officer.
He is currently the Chief Executive Officer & Director at Giiant Pharma, Inc. (since 2021), the President & Chief Executive Officer at Neurenati Therapeutics, Inc. (since 2023), and the Executive Chairman at SemaThera, Inc. (since 2018).
He is also the President & Secretary at Neurasic Therapeutics, Inc. Dr. Ranger's former positions include being a Director at Inversago Pharma, Inc., a Principal at Labopharm, Inc., a Venture Partner at Genesys Capital Partners, Inc., a Principal at Bioxalis Medica, Inc., and a Principal at Thallion Pharmaceuticals, Inc. He obtained his doctorate degree from Université Laval in 2000.
Postes actifs de Maxime Ranger
| Sociétés | Poste | Début |
|---|---|---|
SemaThera, Inc.
 SemaThera, Inc. BiotechnologyHealth Technology SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada. | Président | - |
Neurasic Therapeutics, Inc.
 Neurasic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neurasic Therapeutics, Inc. develops opiate-sparing and pain-relieving drugs. The company was founded in June 2020 and is headquartered in Westmount, Canada. | President | - |
Giiant Pharma, Inc.
 Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Directeur Général | 01/01/2021 |
Anciens postes connus de Maxime Ranger
| Sociétés | Poste | Fin |
|---|---|---|
Genesys Capital Partners, Inc.
 Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | Private Equity Investor | - |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - |
gIcare Pharma, Inc.
 gIcare Pharma, Inc. Pharmaceuticals: MajorHealth Technology gIcare Pharma, Inc. develops gastrointestinal drugs. It develops orally-administered drug GIC-1001 which provides colonic analgesia. The company was founded by Patrick Colin and Maxime Ranger in 2011 and is headquartered in Montreal, Canada. | Fondateur | - |
| THALLION PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Bioxalis Medica, Inc.
 Bioxalis Medica, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ambrilia Biopharma, Inc., Bioxalis Medica, Inc. is a Canadian company that researches cancer treatment and drugs. The company is based in Montréal, Canada. Bioxalis Medica was acquired by Procyon Biopharma, Inc. on June 30, 2005 for $2.79 million. | Corporate Officer/Principal | - |
Formation de Maxime Ranger
| Université Laval | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
Bioxalis Medica, Inc.
Bioxalis Medica, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ambrilia Biopharma, Inc., Bioxalis Medica, Inc. is a Canadian company that researches cancer treatment and drugs. The company is based in Montréal, Canada. Bioxalis Medica was acquired by Procyon Biopharma, Inc. on June 30, 2005 for $2.79 million. | Commercial Services |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
gIcare Pharma, Inc.
gIcare Pharma, Inc. Pharmaceuticals: MajorHealth Technology gIcare Pharma, Inc. develops gastrointestinal drugs. It develops orally-administered drug GIC-1001 which provides colonic analgesia. The company was founded by Patrick Colin and Maxime Ranger in 2011 and is headquartered in Montreal, Canada. | Health Technology |
SemaThera, Inc.
SemaThera, Inc. BiotechnologyHealth Technology SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada. | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Health Technology |
Neurasic Therapeutics, Inc.
Neurasic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neurasic Therapeutics, Inc. develops opiate-sparing and pain-relieving drugs. The company was founded in June 2020 and is headquartered in Westmount, Canada. | Health Technology |
Giiant Pharma, Inc.
Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Health Technology |
Genesys Capital Partners, Inc.
Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | Finance |
